We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cellular Biomedicine Group Inc | NASDAQ:CBMG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 19.74 | 19.74 | 19.80 | 0 | 01:00:00 |
Cellular Biomedicine Group, Inc. |
(Name of Issuer) |
Common Stock, par value $0.001 per share
|
(Title of Class of Securities) |
15117P 102
|
(CUSIP Number) |
WANG MING
Wuhan Dangdai Science&Technology Industries (Group) Co., Ltd .
No.369 Lumo Road
Hongshan District, Wuhan
Hubei Province, China, 430074
With a copy to:
Hunter Taubman Fischer LLC
1450 Broadway, 26
th
Floor
New York, NY 10018
Tel: 917-512-0827
|
(Name, address and telephone number of person
authorized to receive notices and communications)
|
February 4, 2016
|
(Date of event which requires filing of this statement) |
CUSIP No. 15117P 102 | SCHEDULE 13D | Page 2 of 5 Pages |
1
|
NAME OF REPORTING PERSONS
Dangdai International Group Co. Limited
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
o
(b)
o
|
|||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS
OO
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) or 2(e)
o
|
|||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Hong Kong
|
|||
NUMBER OF
|
7
|
SOLE VOTING POWER
|
2,270,000 common stock
|
|
SHARES
BENEFICIALLY
|
8
|
SHARED VOTING POWER
|
0
|
|
OWNED BY
EACH
|
9
|
SOLE DISPOSITIVE POWER
|
2,270,000 common stock
|
|
REPORTING
PERSON WITH
|
10
|
SHARED DISPOSITIVE POWER
|
0
|
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,270,000 common stock
|
|||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
o
|
|||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
16.11%
|
|||
14
|
TYPE OF REPORTING PERSON
CO
|
CUSIP No. 15117P 102 | SCHEDULE 13D | Page 3 of 5 Pages |
(a)
|
Dangdai International beneficially owns 2,270,000 shares of common stock of the Issuer, which represent 16.11 % of the Issuer’s issued and outstanding common stock (based on
14,088,268
shares of the Issuer’s issued and outstanding common stock as of the date of this filing).
|
(b)
|
Dangdai International holds the sole right to vote or direct the vote and sole power to dispose or to direct the disposition of
14,088,268
shares of common stock.
|
CUSIP No. 15117P 102 | SCHEDULE 13D | Page 4 of 5 Pages |
(c)
|
Other than the transaction described herein there has been no other transactions concerning the common stock of the Issuers effected during the past sixty (60) days.
|
(d)
|
HanSheng Zhou, the sole Director of Dangdai International, has the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the shares of common stock beneficially owned by Dangdai International.
|
Exhibit 7.1
|
Share Purchase Agreement
,
dated February 4, 2016 (Incorporated by reference to exhibit 10.1 of the Current Report on Form 8-K that we filed on February 10, 2016);
|
June 23, 2016
|
|
Dated
|
|
/s/ Hansheng Zhou
|
|
Signature
|
|
Director
|
|
Name/Title
|
1 Year Cellular Biomedicine Chart |
1 Month Cellular Biomedicine Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions